Drug Manufacturing

Astria Therapeutics’ navenibart gains orphan medicinal status from EC

Astria Therapeutics received the European Commission's orphan medicinal product designation (OMPD) for navenibart (STAR-0215) to treat hereditary angioedema (HAE).

RTI partners with Codetta Bio to boost healthcare innovation

RTI International has announced a strategic collaboration with Codetta Bio, a company specialising in multi-omics for precision medicine development, to fast-track healthcare innovation.

Samsung Biologics launches biopharmaceutical platform S-HiCon

Samsung Biologics, a contract development and manufacturing organisation (CDMO), has launched S-HiCon, a new high-concentration formulation platform designed to enhance the development and manufacturing of high-dose drugs.

MinervaX collaborates with Wacker Biotech for GBS vaccine production

MinervaX, a Danish biotechnology company, has joined forces with contract development and manufacturing organisation (CDMO) Wacker Biotech for the manufacturing of MinervaX’s active protein ingredients for its Group B Streptococcus (GBS) vaccine.

Persist AI and Nivagen to develop AI-driven LAI manufacturing process

Persist AI and Nivagen have joined forces to co-develop an advanced AI-driven manufacturing process for long-acting injectable (LAI) drugs.

OSR Holdings, SillaJen sign MoU to pursue drug development

Global healthcare holding company OSR Holdings has entered into a memorandum of understanding (MoU) with SillaJen, a South Korea-based biotechnology company with a pipeline of immuno-oncology drug candidates.

AGC completes facility expansion for pDNA and mRNA production line

AGC Biologics has completed the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at Heidelberg, Germany.

Wheeler Bio launches drug substance CGMP facility in Oklahoma City

A biomanufacturing firm Wheeler Bio has launched a drug substance current good manufacturing practices (CGMP) facility in Oklahoma City, US.

Cell therapy CDMO Kincell Bio launches with $36m infusion

Kincell Bio, a cell therapy contract development and manufacturing organisation (CDMO) spun out of Inceptor Bio, has launched with $36m investment with an aim to help early-stage innovators develop and manufacture cell therapies.